Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer
Emilio Garcia‐Mouronte, Emilio Berná‐Rico, Belén de Nicolás-Ruanes, Carlos Azcárraga‐Llobet, Luis Alonso-Martinez de Salinas, Sonia Beá‐Ardébol
Abstract
Cutaneous cancers are, by far, the most common malignant neoplasms of the human being. Due to the great array of clinical conditions, their worldwide increasing incidence and the steady ageing of the population, non-invasive treatments modalities that show a good clinical response, a proper benefit-risk ratio and cosmetic results are becoming increasingly important in the clinical setting. Imiquimod is a topically applied immunomodulator which is often used in the management of several premalignant and malignant cutaneous disorders. This article is a review of the current literature on its mechanism of action, pharmacokinetics, and therapeutical effects.